trial

Treatment of Post Traumatic Stress Disorder in Patients With Other Mental Illnesses

NCTId NCT00053690
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 88
Sponsored by Dartmouth-Hitchcock Medical Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
88
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2002-01
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cognitive Behavior Treatment

Sponsors

Dartmouth-Hitchcock Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

2
Kim Mueser, Ph.D.Principal Investigator
Stanley Rosenberg, Ph.D.Principal Investigator

Sites

1 total
Claremont, United States

Facts & assertions

3 sourced
Enrollment
88
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Behavior Treatment
drug
lead_sponsor
Dartmouth-Hitchcock Medical Center
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Bipolar Disorder
indication
Schizophrenia
indication
Stress Disorders, Post-Traumatic
indication
investigator
Kim Mueser, Ph.D.
person
Stanley Rosenberg, Ph.D.
person